Alexion Pharmaceuticals Inc. (ALXN) and Ophthotech Corporation (NASDAQ:OPHT) Contrasting side by side

As Biotechnology businesses, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Ophthotech Corporation (NASDAQ:OPHT), are affected by compare. This especially applies to their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alexion Pharmaceuticals Inc. 126 5.75 N/A 5.49 20.63
Ophthotech Corporation 1 0.00 N/A 1.70 0.00

In table 1 we can see Alexion Pharmaceuticals Inc. and Ophthotech Corporation’s gross revenue, earnings per share (EPS) and valuation. Ophthotech Corporation is observed to has lower revenue and earnings than Alexion Pharmaceuticals Inc.


Table 2 demonstrates the return on assets, return on equity and net margins of Alexion Pharmaceuticals Inc. and Ophthotech Corporation.

Net Margins Return on Equity Return on Assets
Alexion Pharmaceuticals Inc. 0.00% 14% 9.5%
Ophthotech Corporation 0.00% 0% 0%

Analyst Recommendations

The table delivered features the ratings and recommendations for Alexion Pharmaceuticals Inc. and Ophthotech Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alexion Pharmaceuticals Inc. 0 0 3 3.00
Ophthotech Corporation 0 0 0 0.00

Alexion Pharmaceuticals Inc.’s upside potential is 45.24% at a $167.5 consensus target price.

Insider and Institutional Ownership

Roughly 98.8% of Alexion Pharmaceuticals Inc. shares are held by institutional investors while 65.14% of Ophthotech Corporation are owned by institutional investors. Alexion Pharmaceuticals Inc.’s share held by insiders are 0.3%. Competitively, 0.61% are Ophthotech Corporation’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alexion Pharmaceuticals Inc. -6.35% -13.7% -15.54% -6.62% -13.85% 16.36%
Ophthotech Corporation 0% 0% 0% 0% 0% 0%


Alexion Pharmaceuticals Inc. beats on 11 of the 10 factors Ophthotech Corporation.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.